Reuters: DeepSeek is developing its own AI chips

DeepSeek is reportedly developing its own AI inference chips, hiring engineers and speaking with manufacturing partners as it aims to reduce reliance on third-party suppliers like Huawei and NVIDIA. While export/import restrictions likely limit technology availability outside China, the effort could intensify competition in the Chinese AI chip market and pressure NVIDIA’s positioning if DeepSeek achieves cost/power advantages.

Analysis

The strategic risk is less about this one company and more about China’s willingness to internalize inference economics. If domestic silicon becomes “good enough,” the pressure lands first on NVDA’s China installed base and replacement cycle, not on near-term data-center revenue outside China; that means the first-order earnings hit could be modest while the multiple effect is larger if investors start assigning a lower terminal share of AI capex to U.S. vendors. The most important second-order effect is that a local inference stack would shift spending toward Chinese foundry, packaging, memory, and networking vendors, creating a homegrown ecosystem that compounds over 6-18 months.

Timing matters: over days, this is mostly a sentiment overhang and could matter only if management commentary starts acknowledging share loss or demand uncertainty in China. Over 1-3 months, the catalyst path is evidence of hiring, tapeout, and manufacturing partner commitments; without those, the story remains aspirational and should fade. Over 6-18 months, the real falsifier is whether the domestic chip can match NVDA on perf/W and software tooling enough to support commercial inference deployments at scale; if not, the headline is noise.

Contrarian view: the market may already be discounting a large portion of China risk, so incremental downside may be limited unless this evolves from R&D into production procurement. The cleaner read is that any durable winner is likely outside NVDA in the Chinese AI supply chain, while NVDA only loses meaningfully if domestic inference economics prove both cheaper and operationally stable. That makes this more of a valuation/multiple risk than an immediate revenue shock.

Key Decisions for Investors

• Do not chase NVDA weakness on the headline alone; wait for confirmation via China-order commentary or evidence of domestic tapeouts over the next 1-3 months. Absent that, treat any dip as a sentiment event rather than a fundamental break.
• For a tactical hedge, buy a 1-3 month NVDA put spread on rallies if implied volatility remains contained; risk/reward is best if the market starts pricing China share loss before evidence appears.
• Relative-value idea: short NVDA vs long SOXX/SMH on strength only if broader AI capex stays firm; this expresses China-specific substitution risk while limiting macro beta. Falsify if NVDA re-accelerates gross orders or China restrictions tighten further and reinforce scarcity pricing.
• Set an alert around the next earnings call for any change in China revenue commentary, export-compliance language, or demand normalization; those are the earliest real catalysts that could confirm or dismiss the thesis.